NASDAQ:MACK - Merrimack Pharmaceuticals Stock Price, Forecast & News

Merrimack Pharmaceuticals trades on the NASDAQ under the ticker symbol "MACK."

Merrimack Pharmaceuticals announced a -- dividend on Wednesday, December 4th. Shareholders of record on Monday, December 16th will be given a dividend of $0.50 per share on Monday, December 23rd. The ex-dividend date is Friday, December 13th. View Merrimack Pharmaceuticals' Dividend History.

Shares of Merrimack Pharmaceuticals reverse split on the morning of Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 5th 2017. An investor that had 100 shares of Merrimack Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

Merrimack Pharmaceuticals Inc (NASDAQ:MACK) released its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter. View Merrimack Pharmaceuticals' Earnings History.

Merrimack Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for Merrimack Pharmaceuticals.

News headlines about MACK stock have trended extremely negative recently, according to InfoTrie Sentiment. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Merrimack Pharmaceuticals earned a media sentiment score of -4.3 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Merrimack Pharmaceuticals.

Merrimack Pharmaceuticals saw a decline in short interest in December. As of December 31st, there was short interest totalling 533,500 shares, a decline of 6.8% from the December 15th total of 572,700 shares. Based on an average daily volume of 40,500 shares, the days-to-cover ratio is currently 13.2 days. Approximately 4.2% of the company's stock are sold short. View Merrimack Pharmaceuticals' Current Options Chain.

Some companies that are related to Merrimack Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN), Rite Aid (RAD), Inovio Pharmaceuticals (INO), Anavex Life Sciences (AVXL), Novavax (NVAX), Amicus Therapeutics (FOLD), Gilead Sciences (GILD), Bausch Health Companies (BHC), Exelixis (EXEL) and Verastem (VSTM).

Shares of MACK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MACK stock can currently be purchased for approximately $3.30.

Merrimack Pharmaceuticals has a market capitalization of $44.10 million. Merrimack Pharmaceuticals employs 27 workers across the globe.View Additional Information About Merrimack Pharmaceuticals.

The official website for Merrimack Pharmaceuticals is http://www.merrimackpharma.com/.

Merrimack Pharmaceuticals' mailing address is ONE KENDALL SQUARE SUITE B7201, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-441-1000 or via email at [email protected]